The main molecules proposed in the treatment of NAFLD and T2DM are the GLP-1R and FXR agonists because of their ability to regulate numerous metabolic activities in both the liver and pancreas. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatotic liver disease.